Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 2
1966 9
1967 5
1968 18
1969 15
1970 24
1971 44
1972 40
1973 28
1974 38
1975 28
1976 33
1977 30
1978 41
1979 43
1980 45
1981 45
1982 51
1983 40
1984 44
1985 56
1986 46
1987 40
1988 50
1989 50
1990 55
1991 60
1992 72
1993 69
1994 73
1995 83
1996 79
1997 89
1998 106
1999 127
2000 155
2001 192
2002 213
2003 243
2004 249
2005 269
2006 270
2007 303
2008 315
2009 343
2010 424
2011 431
2012 426
2013 545
2014 528
2015 511
2016 437
2017 436
2018 424
2019 474
2020 545
2021 556
2022 547
2023 501
2024 197

Text availability

Article attribute

Article type

Publication date

Search Results

10,101 results

Results by year

Filters applied: . Clear all
Page 1
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
D'Haens G, Panaccione R, Baert F, Bossuyt P, Colombel JF, Danese S, Dubinsky M, Feagan BG, Hisamatsu T, Lim A, Lindsay JO, Loftus EV Jr, Panés J, Peyrin-Biroulet L, Ran Z, Rubin DT, Sandborn WJ, Schreiber S, Neimark E, Song A, Kligys K, Pang Y, Pivorunas V, Berg S, Duan WR, Huang B, Kalabic J, Liao X, Robinson A, Wallace K, Ferrante M. D'Haens G, et al. Lancet. 2022 May 28;399(10340):2015-2030. doi: 10.1016/S0140-6736(22)00467-6. Lancet. 2022. PMID: 35644154 Clinical Trial.
Crohn's disease.
Dolinger M, Torres J, Vermeire S. Dolinger M, et al. Lancet. 2024 Mar 23;403(10432):1177-1191. doi: 10.1016/S0140-6736(23)02586-2. Epub 2024 Mar 1. Lancet. 2024. PMID: 38437854 Review.
Treatment Algorithms for Crohn's Disease.
Sulz MC, Burri E, Michetti P, Rogler G, Peyrin-Biroulet L, Seibold F; on behalf of the Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology. Sulz MC, et al. Digestion. 2020;101 Suppl 1:43-57. doi: 10.1159/000506364. Epub 2020 Mar 13. Digestion. 2020. PMID: 32172251 Free article. Review.
Pediatric Management of Crohn's Disease.
Mitchel EB, Rosh JR. Mitchel EB, et al. Gastroenterol Clin North Am. 2022 Jun;51(2):401-424. doi: 10.1016/j.gtc.2021.12.013. Epub 2022 Apr 28. Gastroenterol Clin North Am. 2022. PMID: 35595422 Review.
Treat-to-target and sequencing therapies in Crohn's disease.
Garcia NM, Cohen NA, Rubin DT. Garcia NM, et al. United European Gastroenterol J. 2022 Dec;10(10):1121-1128. doi: 10.1002/ueg2.12336. Epub 2022 Dec 12. United European Gastroenterol J. 2022. PMID: 36507876 Free PMC article. Review.
New targets in inflammatory bowel disease therapy: 2021.
Cohen NA, Rubin DT. Cohen NA, et al. Curr Opin Gastroenterol. 2021 Jul 1;37(4):357-363. doi: 10.1097/MOG.0000000000000740. Curr Opin Gastroenterol. 2021. PMID: 34059604 Free PMC article. Review.
Upadacitinib therapy for Crohn's disease.
Kotsiliti E. Kotsiliti E. Nat Rev Gastroenterol Hepatol. 2023 Aug;20(8):483. doi: 10.1038/s41575-023-00812-0. Nat Rev Gastroenterol Hepatol. 2023. PMID: 37369736 No abstract available.
Therapeutic Drug Monitoring of Biologics in Crohn's Disease.
Grossberg LB, Cheifetz AS, Papamichael K. Grossberg LB, et al. Gastroenterol Clin North Am. 2022 Jun;51(2):299-317. doi: 10.1016/j.gtc.2021.12.007. Epub 2022 Apr 27. Gastroenterol Clin North Am. 2022. PMID: 35595416 Review.
10,101 results
You have reached the last available page of results. Please see the User Guide for more information.